These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 24345266)

  • 21. May non-antipsychotic drugs improve cognition of schizophrenia patients?
    Buoli M; Altamura AC
    Pharmacopsychiatry; 2015 Mar; 48(2):41-50. PubMed ID: 25584772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice.
    Park SM; Chen M; Schmerberg CM; Dulman RS; Rodriguiz RM; Caron MG; Jin J; Wetsel WC
    Neuropsychopharmacology; 2016 Feb; 41(3):704-15. PubMed ID: 26129680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glutamate and modeling of schizophrenia symptoms: review of our findings: 1990-2014.
    Gargiulo PÁ; Landa De Gargiulo AI
    Pharmacol Rep; 2014 Jun; 66(3):343-52. PubMed ID: 24905508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in treating cognitive impairment in schizophrenia.
    Galletly C
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):259-73. PubMed ID: 18766331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
    Citrome L
    J Clin Psychiatry; 2014; 75 Suppl 1():21-6. PubMed ID: 24581451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.
    Paz RD; Tardito S; Atzori M; Tseng KY
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):773-86. PubMed ID: 18650071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophrenia.
    Denis Goetghebeur PJ; Dias R
    Curr Pharm Des; 2014; 20(31):5060-8. PubMed ID: 24345267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?
    Dunlop J; Brandon NJ
    J Psychopharmacol; 2015 Feb; 29(2):230-8. PubMed ID: 25586401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
    Goff DC; Coyle JT
    Am J Psychiatry; 2001 Sep; 158(9):1367-77. PubMed ID: 11532718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of cognitive impairment in schizophrenia.
    Goff DC; Hill M; Barch D
    Pharmacol Biochem Behav; 2011 Aug; 99(2):245-53. PubMed ID: 21115035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia.
    Gill KM; Grace AA
    Curr Pharm Des; 2014; 20(31):5069-76. PubMed ID: 24345268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
    Zhang HT
    IDrugs; 2010 Mar; 13(3):166-8. PubMed ID: 20191432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.